Note 9. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

    

Year Ended June 30, 

    

2025

    

2024

    

2023

Earnings per share – basic:

Net earnings, including noncontrolling interest

$

73,400

 

$

168,105

 

$

285,442

Less net earnings attributable to noncontrolling interest

179

Net earnings attributable to Bio-Techne

$

73,400

$

168,105

$

285,263

Income allocated to participating securities

 

(37)

 

(33)

 

(70)

Income available to common shareholders

$

73,363

$

168,072

$

285,193

Weighted-average shares outstanding – basic

 

157,521

 

157,708

 

157,179

Earnings per share – basic

$

0.47

$

1.07

$

1.81

Earnings per share – diluted:

 

  

 

  

 

  

Net earnings, including noncontrolling interest

$

73,400

$

168,105

$

285,442

Less net earnings attributable to noncontrolling interest

179

Net earnings attributable to Bio-Techne

$

73,400

$

168,105

$

285,263

Income allocated to participating securities

 

(37)

 

(33)

 

(70)

Income available to common shareholders

$

73,363

$

168,072

$

285,193

Weighted-average shares outstanding – basic

 

157,521

 

157,708

 

157,179

Dilutive effect of stock options and restricted stock units

 

2,196

 

3,066

 

4,676

Weighted-average common shares outstanding – diluted

 

159,717

 

160,774

 

161,855

Earnings per share – diluted

$

0.46

$

1.05

$

1.76

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 3.8 million, 3.9 million, and 4.5 million for fiscal 2025, 2024 and 2023, respectively.

Historical Timeline

Fiscal YearFiled
2025Aug 22, 2025Showing above
2024Aug 22, 2024
2023Aug 23, 2023
2022Aug 24, 2022
2021Aug 25, 2021
2020Aug 26, 2020
2019Aug 28, 2019
2018Aug 27, 2018
2017Sep 7, 2017
2016Aug 29, 2016

About Earnings Per Share Disclosures

The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.

Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.